|Articles|June 1, 2005
Santen CEO joins OccuLogix board
Napa, CA—Santen Inc.'s president and chief executive officer, Adrienne L. Graves, PhD, has joined the OccuLogix Inc. board of directors.
Advertisement
Before she became president in 2002, Dr. Graves was vice president of clinical affairs for Santen and helped to move three ophthalmic products through the FDA approval process. Prior to her work with Santen, Dr. Graves worked for Alcon Laboratories Inc.
Elias Vamvakas, OccuLogix's chairman and chief executive officer, said the company would benefit from Dr. Graves' involvement in the clinical, regulatory, and commercial development of the RHEO procedure.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA)
2
Tinlarebant NDA submission completed for Stargardt disease type 1, targeting first approved therapy
3
Expanding the ICRS toolkit: Keraring for high regular astigmatism
4
Study finds mixed real and synthetic eye images enhance ocular AI performance
5